Our multi-target mechanism studies using molecular docking thus showed a shared binding residues (Gln281) with reference drugs for ACE inhibition, 3 H-bonds by Isorhamnetin-3-O-glucoside vs. 0–1 in standard antagonists for VGCC blockade and a polypharmacological potential through a simultaneous ACE/AT1R/VGCC modulation, which can address hypertension synergistically. Here, AGTR1 is linked to hypertensive disorder.